Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Episurf Regulatory Filings 2016

Sep 12, 2016

3157_rns_2016-09-12_06dd3883-7dad-4d77-b528-d3dd2cb29376.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

Company Announcement September 12, 2016

Episurf Medical AB to present at Aktiedagen, held in Gothenburg on September 26

Episurf Medical AB will present at Aktiedagen, an investor conference held in Gothenburg (Svenska Mässan) on September 26. The company will be represented by CFO Pål Ryfors. For full program and registration,see link. (http://www.aktiespararna.se).

For more information, please contact:

Pål Ryfors, CFO, Episurf Medical Tel: +46 709 62 36 69 Email: [email protected]

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 12 September 2016.